Skip to content

Study · Non-randomized trial · n = 24 · 1989

8 results

The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency.

Salomon F, Cuneo RC, Hesp R, Sönksen PH

The New England journal of medicine1 Dec 1989Cited by 770 (Europe PMC)

PMID2687691 (opens in a new tab)DOI10.1056/nejm198912283212605 (opens in a new tab)PepBankPUB-02687691
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, rhGH lowered fasting plasma cholesterol versus placebo (P less than 0.05).

    In plain wordsIn GH-deficient adults, rhGH lowered fasting cholesterol compared with placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseFasting plasma cholesterol
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.07 U/kg daily at bedtime · subcutaneous · six monthsAs given in this study (human).

    Source sentences

    Summary
    Fasting plasma cholesterol levels were lower (P less than 0.05) in the rhGH-treated group than in the placebo group, whereas plasma triglyceride values were similar in the two groups throughout the study.
    3 context sentences
    Summary · context
    In a double-blind, placebo-controlled trial, we studied the effects of six months of growth hormone replacement in 24 adults with growth hormone deficiency.
    Summary · context
    Most of the patients had acquired growth hormone deficiency during adulthood as a consequence of treatment for pituitary tumors, and all were receiving appropriate thyroid, adrenal, and gonadal hormone replacement.
    Summary · context
    The daily dose of recombinant human growth hormone (rhGH) was 0.07 U per kilogram of body weight, given subcutaneously at bedtime.
  2. 02HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, plasma triglycerides were similar with rhGH and placebo throughout the study.

    In plain wordsIn GH-deficient adults, blood triglycerides were similar with rhGH and placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changePlasma triglycerides
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.07 U/kg daily at bedtime · subcutaneous · six monthsAs given in this study (human).

    Source sentences

    Summary
    Fasting plasma cholesterol levels were lower (P less than 0.05) in the rhGH-treated group than in the placebo group, whereas plasma triglyceride values were similar in the two groups throughout the study.
    3 context sentences
    Summary · context
    In a double-blind, placebo-controlled trial, we studied the effects of six months of growth hormone replacement in 24 adults with growth hormone deficiency.
    Summary · context
    Most of the patients had acquired growth hormone deficiency during adulthood as a consequence of treatment for pituitary tumors, and all were receiving appropriate thyroid, adrenal, and gonadal hormone replacement.
    Summary · context
    The daily dose of recombinant human growth hormone (rhGH) was 0.07 U per kilogram of body weight, given subcutaneously at bedtime.
  3. 03HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, rhGH increased plasma IGF I from 0.41 to 1.53 U per liter.

    In plain wordsIn GH-deficient adults, rhGH increased plasma IGF I from baseline.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreasePlasma IGF I
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.07 U/kg daily at bedtime · subcutaneous · six monthsAs given in this study (human).

    Measurements

    IGF I
    0.41 U per liter
    baseline
    IGF I
    1.53 U per liter
    rhGH

    Source sentences

    Summary
    The mean (+/- SE) plasma concentration of insulin-like growth factor I increased from 0.41 +/- 0.05 to 1.53 +/- 0.16 U per liter during rhGH treatment.
    3 context sentences
    Summary · context
    In a double-blind, placebo-controlled trial, we studied the effects of six months of growth hormone replacement in 24 adults with growth hormone deficiency.
    Summary · context
    Most of the patients had acquired growth hormone deficiency during adulthood as a consequence of treatment for pituitary tumors, and all were receiving appropriate thyroid, adrenal, and gonadal hormone replacement.
    Summary · context
    The daily dose of recombinant human growth hormone (rhGH) was 0.07 U per kilogram of body weight, given subcutaneously at bedtime.
  4. 04HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, rhGH had no effect on body weight.

    In plain wordsIn GH-deficient adults, rhGH did not change body weight.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeBody weight
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.07 U/kg daily at bedtime · subcutaneous · six monthsAs given in this study (human).

    Source sentences

    Summary
    Treatment with rhGH had no effect on body weight.
    3 context sentences
    Summary · context
    In a double-blind, placebo-controlled trial, we studied the effects of six months of growth hormone replacement in 24 adults with growth hormone deficiency.
    Summary · context
    Most of the patients had acquired growth hormone deficiency during adulthood as a consequence of treatment for pituitary tumors, and all were receiving appropriate thyroid, adrenal, and gonadal hormone replacement.
    Summary · context
    The daily dose of recombinant human growth hormone (rhGH) was 0.07 U per kilogram of body weight, given subcutaneously at bedtime.
  5. 05HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, rhGH increased lean body mass by 5.5 +/- 1.1 kg (P less than 0.0001).

    In plain wordsIn GH-deficient adults, rhGH increased lean body mass from baseline, while placebo produced no significant change.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLean body mass
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body composition · Musculoskeletal
    Studied dose
    0.07 U/kg daily at bedtime · subcutaneous · six monthsAs given in this study (human).

    Measurements

    Lean body mass increase
    5.5 kg
    rhGH

    Source sentences

    Summary
    The mean lean body mass, however, increased by 5.5 +/- 1.1 kg (P less than 0.0001), and the fat mass decreased by 5.7 +/- 0.9 kg (P less than 0.0001) in the group treated with growth hormone; neither changed significantly in the placebo group.
    3 context sentences
    Summary · context
    In a double-blind, placebo-controlled trial, we studied the effects of six months of growth hormone replacement in 24 adults with growth hormone deficiency.
    Summary · context
    Most of the patients had acquired growth hormone deficiency during adulthood as a consequence of treatment for pituitary tumors, and all were receiving appropriate thyroid, adrenal, and gonadal hormone replacement.
    Summary · context
    The daily dose of recombinant human growth hormone (rhGH) was 0.07 U per kilogram of body weight, given subcutaneously at bedtime.
  6. 06HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, rhGH reduced fat mass by 5.7 +/- 0.9 kg (P less than 0.0001).

    In plain wordsIn GH-deficient adults, rhGH reduced fat mass from baseline, while placebo produced no significant change.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseFat mass
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    0.07 U/kg daily at bedtime · subcutaneous · six monthsAs given in this study (human).

    Measurements

    Fat mass decrease
    5.7 kg
    rhGH

    Source sentences

    Summary
    The mean lean body mass, however, increased by 5.5 +/- 1.1 kg (P less than 0.0001), and the fat mass decreased by 5.7 +/- 0.9 kg (P less than 0.0001) in the group treated with growth hormone; neither changed significantly in the placebo group.
    3 context sentences
    Summary · context
    In a double-blind, placebo-controlled trial, we studied the effects of six months of growth hormone replacement in 24 adults with growth hormone deficiency.
    Summary · context
    Most of the patients had acquired growth hormone deficiency during adulthood as a consequence of treatment for pituitary tumors, and all were receiving appropriate thyroid, adrenal, and gonadal hormone replacement.
    Summary · context
    The daily dose of recombinant human growth hormone (rhGH) was 0.07 U per kilogram of body weight, given subcutaneously at bedtime.
  7. 07HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, rhGH increased basal metabolic rate from 32.4 to 37.2 kcal/kg lean body mass/day after one month (P less than 0.001).

    In plain wordsIn GH-deficient adults, rhGH increased basal metabolic rate from baseline after one month.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseBasal metabolic rate at one month
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    0.07 U/kg daily at bedtime · subcutaneous · six monthsAs given in this study (human).

    Measurements

    Basal metabolic rate
    32.4 kcal per kilogram of lean body mass per day
    baseline
    Basal metabolic rate
    37.2 kcal per kilogram of lean body mass per day
    one month

    Source sentences

    Summary
    The basal metabolic rate, measured at base line and after one and six months of rhGH administration, increased significantly; the respective values were 32.4 +/- 1.4, 37.2 +/- 2.2, and 34.4 +/- 1.6 kcal per kilogram of lean body mass per day (P less than 0.001 for both comparisons).
    3 context sentences
    Summary · context
    In a double-blind, placebo-controlled trial, we studied the effects of six months of growth hormone replacement in 24 adults with growth hormone deficiency.
    Summary · context
    Most of the patients had acquired growth hormone deficiency during adulthood as a consequence of treatment for pituitary tumors, and all were receiving appropriate thyroid, adrenal, and gonadal hormone replacement.
    Summary · context
    The daily dose of recombinant human growth hormone (rhGH) was 0.07 U per kilogram of body weight, given subcutaneously at bedtime.
  8. 08HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, rhGH increased basal metabolic rate from 32.4 to 34.4 kcal/kg lean body mass/day after six months (P less than 0.001).

    In plain wordsIn GH-deficient adults, rhGH increased basal metabolic rate from baseline after six months.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseBasal metabolic rate at six months
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    0.07 U/kg daily at bedtime · subcutaneous · six monthsAs given in this study (human).

    Measurements

    Basal metabolic rate
    32.4 kcal per kilogram of lean body mass per day
    baseline
    Basal metabolic rate
    34.4 kcal per kilogram of lean body mass per day
    six months

    Source sentences

    Summary
    The basal metabolic rate, measured at base line and after one and six months of rhGH administration, increased significantly; the respective values were 32.4 +/- 1.4, 37.2 +/- 2.2, and 34.4 +/- 1.6 kcal per kilogram of lean body mass per day (P less than 0.001 for both comparisons).
    3 context sentences
    Summary · context
    In a double-blind, placebo-controlled trial, we studied the effects of six months of growth hormone replacement in 24 adults with growth hormone deficiency.
    Summary · context
    Most of the patients had acquired growth hormone deficiency during adulthood as a consequence of treatment for pituitary tumors, and all were receiving appropriate thyroid, adrenal, and gonadal hormone replacement.
    Summary · context
    The daily dose of recombinant human growth hormone (rhGH) was 0.07 U per kilogram of body weight, given subcutaneously at bedtime.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT03878992

Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle

University of Aarhusn = 1230 Apr 2019 to est. 31 Dec 2021

Growth Hormone Deficiency · Growth Hormone Treatment

Trial pageClinicalTrials.govUpdated 26 Sept 2019
CompletedNot applicableNCT00136032

Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women

Massachusetts General Hospitaln = 63Jan 2002 to Nov 2006

Growth Hormone Deficiency

Trial pageClinicalTrials.govUpdated 18 Feb 2008

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.